Press Releases Alligator Bioscience AB

Equities

ATORX

SE0000767188

Delayed Nasdaq Stockholm Other stock markets 07:26:21 2024-04-29 am EDT			5-day change	1st Jan Change
0.907 ^SEK	-1.95%		-8.75%	+31.64%

Apr. 26	Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement	CI
Apr. 05	Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alligator Bioscience and Orion Corporation announce exercise of development option under 2021 Immuno-oncology Research Collaboration and License Agreement	Apr. 26	AQ
Last day of trading in paid subscribed units (Sw. BTU) in Alligator	Apr. 18	AQ
Alligator publishes outcome in rights issue	Apr. 09	AQ
Alligator Bioscience Announces Two Presentations on Mitazalimab and ATOR-4066 at the AACR Annual Meeting 2024	Apr. 08	AQ
Notice of annual general meeting in Alligator Bioscience AB	Apr. 05	AQ
BioStock: Alligator Bioscience on the importance of prolonging life	Apr. 02	AQ
BioStock: Alligator to maximise immuno-oncology innovation	Mar. 27	AQ
Alligator Bioscience Announces Publication Highlighting its RUBY® Bispecific Antibody Format in the Scientific Journal "mAbs"	Mar. 26	AQ
Alligator publishes supplementary prospectus	Mar. 22	AQ
Alligator Bioscience publishes Annual Report for 2023	Mar. 21	AQ
Alligator Bioscience : The subscription period in Alligator Bioscience's rights issue begins today	Mar. 21	PU
BioStock: Alligator's CEO on current development and the rights issue	Mar. 21	AQ
The subscription period in Alligator Bioscience’s rights issue begins today	Mar. 21	AQ
Alligator Bioscience publishes prospectus in connection with forthcoming rights issue	Mar. 15	AQ
Bulletin from the extraordinary general meeting in Alligator Bioscience AB	Mar. 14	AQ
BioStock: Clinical effects observed with Alligator's 4-1BB agonist	Mar. 14	AQ
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4	Mar. 07	AQ
BioStock: Alligator prepares for phase III with CD40 agonist	Feb. 20	AQ
BioStock: Alligator's CEO comments on restructuring plan	Feb. 16	AQ
Alligator Bioscience Q4 2023 - Strong Topline Data and Rights Issue	Feb. 12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Alligator Bioscience AB

Equities

ATORX

SE0000767188

Press Releases

Filters